Long-term Outcomes After Bladder Preserving Combined Modality Therapy for Muscle-invasive Bladder Cancer: A Pooled Analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233 von Mak, R.H, Hunt, D, Shipley, W.U, Efstathiou, J.A, Yan, Y, Tester, W.J, Hagan, M.P, Kaufman, D.S, Heney, N.M, Zietman, A.L

Volltext

41 [formula omitted]: A Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation thera... von Shipley, W.U., Winter, K.A., Lee, R., Kaufman, D.S., Heney, N.M., Tester, W.J., Venner, P.M., Perez, C.A., Murray, K.A., Doggett, R.L.S.

Volltext

873 KadianTM/kapanolTM—A once daily morphine formulation von Broomhead, A.F., Kerr, R.O., Tester, W.J., Bowles, R.L., Maccarrone, C., Hodsman, G.P.

Volltext

873 Kadian TM/kapanol TM—A once daily morphine formulation von Broomhead, A.F., Kerr, R.O., Tester, W.J., Bowles, R.L., Maccarrone, C., Hodsman, G.P.

Volltext

CALMODULIN MUTATION (CALM1-E141G) ASSOCIATED WITH LONG QT SYNDROME DISRUPTS CALMODULIN CALCIUM BINDING AND IMPAIRS L-TYPE CA CHANNEL INACTIVATION von Gomez-Hurtado, N, Kryshtal, D.O, Hwang, H.S, Johnson, C.N, Chazin, W.J, Boczek, N.J, Tester, D.J, Ye, D, Will, M.L, Ackerman, M.J, Knollmann, B.C

Volltext

2014-A-42-CES - CALMODULIN MUTATION (CALM1-E141G) ASSOCIATED WITH LONG QT SYNDROME DISRUPTS CALMODULIN CALCIUM BINDING AND IMPAIRS L-TYPE CA CHANNEL INACTIVATION von Gomez-Hurtado, N., Kryshtal, D.O., Hwang, H.S., Johnson, C.N., Chazin, W.J., Boczek, N.J., Tester, D.J., Ye, D., Will, M.L., Ackerman, M.J., Knollmann, B.C.

Volltext